Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2152W HIGH $43.50
Volume
16.72 K
Value Traded
61.93 K
Short % Float
1%
+5.22%Week
-10.15%1 Month
-26.22%3 Month
-33.52%6 Month
-96.83%5 Year
-96.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.85 M
EPS (TTM)
-3.42
P/E Ratio
-
Ent. Value
2.32 M
Total Shares
3.26 M
Float Shares
3.14 M
Insiders
3.92%
Institutions
20.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Intensity Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intensity Therapeutics, Inc.
179Total events
9Upcoming
20Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Intensity Therapeutics to participate in H.C. Wainwright 28th Annual Global Investment Conference
▲Interim Efficacy DataINT230-6Clinical Data
Preliminary data from first 14 patients showed 71% pCR in Cohort A vs 42% in Cohort B
triple negative breast cancersource ↗
▲FDA Feedback ReceivedINT230-6FDA Meeting
FDA reviewed amended protocol for INVINCIBLE-3
soft tissue sarcomasource ↗
◆Other Regulator MilestoneINT230-6Ex-US Regulatory
Submission of documentation for restarting in EU in progress
soft tissue sarcomasource ↗
●Equity OfferingCorporate
Raised additional net proceeds of $1.3 million under ATM subsequent to June 30, 2026
▲Trial InitiationINT230-6Trial
Opened first site in France for accrual in INVINCIBLE-4
triple negative breast cancersource ↗
●Equity OfferingCorporate
Raised additional net proceeds of $1.3 million under ATM subsequent to June 30, 2026
▲First Patient DosedINT230-6Trial
First patients dosed in Switzerland in INVINCIBLE-4 Study
triple-negative breast cancersource ↗
●Enrollment UpdateINT230-6Trial
Trial restarted after pause; 14 patients treated prior to pause; additional 47 patients expected to enroll
triple-negative breast cancersource ↗
▲Enrollment UpdateINT230-6Trial
Resume enrollment in limited U.S. sites in INVINCIBLE-3 by Q3 2026
soft tissue sarcomasource ↗
▲PublicationINT230-6Presentation
Peer-reviewed publication in eBioMedicine (Lancet Discovery Science) reporting clinical observations
advanced solid tumorssource ↗
▲First Patient DosedINT230-6Trial
Restarted patient treatment in INVINCIBLE-4 Study
triple negative breast cancersource ↗
▲Partnership / LicenseINT230-6Corporate
Active strategic partnering initiatives; over 20 partnering discussions at BIO 2026
●Partnership / LicenseCorporate
Held meetings with potential strategic partners at BIO International Conference
▲Enrollment UpdateINT230-6Trial
Initiated activities to resume enrollment in limited U.S. sites in INVINCIBLE-3
soft tissue sarcomasource ↗
▲Trial InitiationINT230-6Trial
Initiated activities to resume enrollment in limited U.S. sites
soft tissue sarcomasource ↗
▲IND ClearanceINT230-6IND
Full approval to resume enrollment in INVINCIBLE-4 granted by Swissmedic and Swiss Ethics Committee
presurgical triple-negative breast cancersource ↗
▲Enrollment PausedINT230-6Trial
Enrollment paused; approval to resume granted March 26, 2026
triple negative breast cancersource ↗
▲Safety Data UpdateINT230-6Clinical Data
Safety data through March 2, 2026 shows favorable safety for INT230-6 plus SOC vs SOC alone
triple-negative breast cancersource ↗
●Protocol AmendmentINT230-6Trial
Protocol amendment approved by Swissmedic and Swiss Ethics Committee for lower drug volume and single injection
triple negative breast cancersource ↗
▲Topline ReadoutINT230-6Clinical Data
Preliminary observations reported: 5/7 pCR in Cohort A vs 2/6 in Cohort B
triple negative breast cancersource ↗
▲Enrollment UpdateINT230-6Trial
Trial restarted after pause; protocol amendment submitted in March 2026
triple-negative breast cancersource ↗
▼Reverse Stock SplitCorporate
1-for-25 reverse stock split approved by board and stockholders
●Enrollment UpdateINT230-6Trial
Expects to reinitiate enrollment in Q1 2026
early-stage, operable triple-negative breast cancersource ↗
●Protocol AmendmentINT230-6Trial
Plan to file protocol amendment for dosing revision
early-stage, operable triple-negative breast cancersource ↗
◆Enrollment CompleteINT230-6Trial
Expected enrollment completion in INVINCIBLE-4 Study
triple-negative breast cancersource ↗
◆Poster PresentationINT230-6Presentation
Poster presentation of intratumoral injections of INT230-6 prior to neoadjuvant immuno-chemotherapy in early-stage TNBC
early-stage triple negative breast cancersource ↗
◆Poster PresentationINT230-6Presentation
Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations
breast cancersource ↗
●Protocol AmendmentINT230-6Trial
Protocol modification to administer a single dose at lower volumes for each tumor size
early-stage triple negative breast cancersource ↗
●Enrollment UpdateINT230-6Trial
14 patients treated to date in INVINCIBLE-4 study
early-stage triple negative breast cancersource ↗
▼Enrollment PausedINT230-6Trial
Patient enrollment paused to implement modified dosing regimen
early-stage triple negative breast cancersource ↗
◆Timing GuidanceINT230-6Presentation
Plan to restart patient enrollment in INVINCIBLE-4 using modified dosing regimen as soon as possible
early-stage triple negative breast cancersource ↗
▲Quarterly UpdateCorporate
Granted 180-day extension to regain Nasdaq minimum bid price compliance
◆Oral PresentationINT230-6Presentation
Webinar with lead and senior authors to discuss published results
metastatic or refractory cancerssource ↗
▲PublicationINT230-6Presentation
Publication of phase 1/2 IT-01 clinical study manuscript in eBioMedicine
metastatic or refractory cancerssource ↗
▲PublicationINT230-6Presentation
Publication of Phase 1/2 IT-01 study manuscript in eBioMedicine (Lancet Discovery Science)
metastatic or refractory cancerssource ↗
▼Enrollment PausedINT230-6Trial
Enrollment paused in Cohort A due to localized skin irritation
triple-negative breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How INTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | INT230-6 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$2M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 63%
Micro Cap(rank 416 of 660)
Percentile Rank
Intensity Therapeutics, Inc. faces pipeline headwinds (32/100), with $206M risk-adjusted pipeline value, led by INT230-6 in Breast Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INT230-6 Small moleculeNCT06263231 | Sarcoma,Soft Tissue | Phase 3 | RECRUITING | 333 | Dec 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every INTS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wesolowski John MOfficer (Principal Accounting Officer) | Grant/Award | 3,688 7,102 held | $3.49 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INTS for Q2 2026. | ||||
INTS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INTS ranks across every disease it competes in
Competitive Position is a premium feature
See how INTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINTS News
INTSIntensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Intensity Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company will present its lead product candidate, INT230-6, which is designed for direct intratumoral injection and has shown potential in treating various cancers. A live webcast of the presentation will be available, and the CEO will hold one-on-one meetings during the event.
Read more →INTSIntensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Intensity Therapeutics reported its second quarter 2026 financial results, highlighting the resumption of patient treatment in the Phase 2 INVINCIBLE-4 Study and plans to restart enrollment in the Phase 3 INVINCIBLE-3 Study. The company raised $1.6 million under its ATM facility and is pursuing additional funding. Preliminary data from INVINCIBLE-4 shows promising pathological complete response rates. However, the company also reported a net loss of $3.0 million for the quarter.
Read more →INTSIntensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Intensity Therapeutics will announce its second quarter 2026 financial results on August 11, 2026, before market opening. A conference call will follow at 8 AM ET to discuss the results and provide a corporate update. The company is focused on developing intratumoral cancer therapies, with its lead candidate INT230-6 showing potential in clinical trials.
Read more →INTSIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics has resumed patient treatment in the INVINCIBLE-4 Study, focusing on INT230-6 for presurgical triple-negative breast cancer. The trial evaluates the efficacy of INT230-6 combined with standard-of-care immuno-chemotherapy against standard treatment alone. Early data suggests a favorable safety profile and potential for improved pathological complete response rates. The study aims to enroll an additional 47 patients in Switzerland and France.
Read more →INTSIntensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Intensity Therapeutics provided a mid-year update on its late-stage development programs, particularly focusing on INT230-6 for soft tissue sarcoma and presurgical triple-negative breast cancer. The company reported positive preliminary outcomes from clinical studies and is actively pursuing strategic partnerships to enhance development. Despite some funding constraints affecting enrollment, Intensity's financial position remains strong.
Read more →INTSIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics has been recognized as the Cancer Treatment Technology Innovator of the Year 2026 by GHP Magazine. This award highlights the company's innovative approach to cancer therapies, particularly its lead product INT230-6, which has shown encouraging results in clinical trials for patients with advanced cancers. The recognition underscores Intensity's commitment to improving cancer care and patient outcomes.
Read more →INTSIntensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics has reported favorable preliminary results from its INVINCIBLE-4 Study in early-stage triple negative breast cancer patients, indicating improved efficacy with its drug INT230-6. The company plans to resume enrolling patients in both INVINCIBLE-4 and INVINCIBLE-3 Studies by mid-2026, contingent upon securing additional funding. Financially, Intensity reported a lower net loss in the first quarter of 2026 compared to the same period last year, alongside cash reserves of $10.2 million. The ongoing focus remains on developing effective cancer therapies addressing high unmet needs.
Read more →INTSIntensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Intensity Therapeutics has been awarded the Platinum Award for Innovator in Biotech Solutions at the 2026 Pinnacle Awards for its lead drug candidate INT230-6. This investigational product is designed for direct intratumoral injection and combines two potent anti-cancer agents. The award underscores the company's innovative approach to cancer treatment and its potential to change the treatment landscape.
Read more →INTS▼ -5.8%on this news
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Intensity Therapeutics provided a corporate update alongside its 2025 financial results, highlighting the ongoing INVINCIBLE-4 and INVINCIBLE-3 studies. The company has raised over $20 million to extend its cash runway and plans to resume patient enrollment in its trials. Despite a net loss of $11.6 million, the company remains optimistic about its novel cancer therapy, INT230-6.
Read more →INTSIntensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics announced the issuance of a new US patent, enhancing its intellectual property portfolio. The patent, US Patent Number 12,496,345, is part of the company's efforts to protect its innovative cancer therapies. With four US patents and coverage in 41 countries, Intensity aims to advance its lead product candidate, INT230-6, in ongoing clinical trials.
Read more →INTS▼ -6.2%on this news· ran to -18% by day 3
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics has provided an update on its Phase 2 INVINCIBLE-4 study for presurgical triple-negative breast cancer. The study's enrollment was paused due to skin irritations, but a protocol amendment has been submitted to resume using a lower drug volume. Preliminary data shows promising pCR rates and favorable safety profiles compared to standard treatments. The company plans to present more detailed results at an upcoming oncology conference.
Read more →INTSIntensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics, Inc. has announced that it has regained compliance with Nasdaq's listing requirements after its stock maintained a bid price above $1.00 for ten consecutive business days. This announcement indicates strong market performance and supports the company’s ongoing development of its lead product, INT230-6, which is undergoing several clinical trials for various cancers. The therapy represents a novel approach to cancer treatment, aiming to improve both local control and systemic immune response.
Read more →INTS▼ -32.6%on this news
Intensity Therapeutics Announces Reverse Stock Split
Intensity Therapeutics has announced a 1-for-25 reverse stock split, effective February 18, 2026, to comply with Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares significantly while maintaining the total authorized shares. The company continues to advance its investigational product INT230-6, which targets cancer treatment through direct intratumoral injection.
Read more →INTSIntensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Intensity Therapeutics has outlined its strategic priorities for 2026, highlighting key achievements from 2025. The company emphasizes its clinically validated product INT230-6, which is designed for direct tumor injection and shows promise in cancer treatment. With a strengthened balance sheet, Intensity aims to advance its clinical programs and regulatory engagements while focusing on generating high-quality clinical data.
Read more →INTS▲ +7.3%on this news· ran to -20% by day 3
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. will present two posters at the 2025 San Antonio Breast Cancer Symposium, showcasing early observations from the INVINCIBLE-4 study on INT230-6 for treating Triple Negative Breast Cancer (TNBC). The presentations highlight potential modifications to treatment protocols and the promise of a safer alternative to traditional therapies. The company aims to advance to a Phase 3 trial based on favorable safety and efficacy results.
Read more →INTS▲ +10.8%on this news
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for ten consecutive business days by June 1, 2026. This extension follows an initial compliance period that expired on December 3, 2025. The company is actively monitoring its stock price to regain compliance.
Read more →INTS▲ +12.3%on this news· ran to +29% by day 3shared move
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics has announced two presentations at the 2025 San Antonio Breast Cancer Symposium, showcasing their lead product candidate INT230-6. This investigational drug is designed for direct intratumoral injection and combines two potent anti-cancer agents with a unique enhancer. The company aims to demonstrate its potential to improve cancer treatment outcomes and engage the immune system effectively.
Read more →INTS▼ -6.2%on this news
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics reported its third quarter 2025 financial results, highlighting a successful fundraising effort that extended its cash runway until early 2027. The company plans to resume patient enrollment in its INVINCIBLE-4 study after revising the dosing regimen due to localized skin irritation in some patients. Additionally, a peer-reviewed publication on INT230-6 supports its efficacy in treating advanced solid tumors.
Read more →INTS▼ -44.7%on this news· ran to -57% by day 3
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Intensity Therapeutics, Inc. has announced a $4 million registered direct offering of common stock at $0.80 per share. The offering is expected to close around November 3, 2025, and will help fund clinical trials and general corporate purposes. The company anticipates having sufficient cash runway until the end of Q1 2027.
Read more →INTS▲ +394.6%on this newsshared move
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Intensity Therapeutics, Inc. announced the publication of its phase 1/2 study results for INT230-6 in treating metastatic or refractory cancers in eBioMedicine. The study demonstrated promising efficacy and a favorable safety profile, with notable immune activation and abscopal effects. A webinar will be held to discuss the findings further.
Read more →About Intensity Therapeutics, Inc.
Headquarters1 ENTERPRISE DRIVE, SUITE 430, SHELTON, CT, 06484
BIOPHARMAWATCH ELITE PLUS
Trade the next INTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime